Curcumin has long been expected to be a therapeutic or preventive agent for several major human diseases because of its antioxidative, anti-inflammatory, and anticancerous effects. In phase I clinical studies, curcumin with doses up to 3600–8000 mg daily for 4 months did not result in discernible toxicities except mild nausea and diarrhea. The pharmacokinetic studies of curcumin indicated in general a low bioavailability of curcumin following oral application. Nevertheless, the pharmacologically active concentration of curcumin could be achieved in colorectal tissue in patients taking curcumin orally and might also be achievable in tissues such as skin and oral mucosa, which are directly exposed to the drugs applied locally or topically.
- Cervical Intraepithelial Neoplasia
- Advanced Colorectal Cancer
- Colorectal Tissue
- Oral Leukoplakia
- Chronic Anterior Uveitis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Unable to display preview. Download preview PDF.
1. K. L. Grant and C. D. Schneider, Tumeric. Am J Health-Syst Pharm 57, 1121–1122 (2000).
2. J. K. Lin and S. Y. Lin-Shiau, Mechanisms of cancer chemoprevention by curcumin. Proc Natl Sci Counc Repub China B. 25(2), 59–66 (2001).
3. B. B. Aggarwal, A. Kumar, and A. C. Bharti, Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23, 363–398.
4. B. Joe, M. Vijaykumar, and B. R. Lokesh, Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 44(2), 97–111 (2004).
5. R. A. Sharma, A. J. Gescher, and W. P. Steward, Curcumin: The story so far. Eur J Cancer 41, 1995–1968 (2004).
6. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., Shen, T. S., Ko, J. Y., Lin, J. T., Lin, B. R., Wu, M. S., Yu, H. S., Jee, S. H., Chen, G. S., Chen, T. M., Chen, C. A., Lai, M. K., Pu, Y. S., Pan, M. H., Wang, Y. J., Tsai, C. C., and Hsieh, C. Y., 2001, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high–risk or pre–malignant lesions. Anticancer Res 21, 2895–2900.
7. R. A. Sharma, H. R. McLelland, K. A. Hill, C. R. Ireson, S. A. Euden, M. M. Manson, M. Pirmohamed, L. J. Marnett, A. J. Gescher, and W. P. Steward, Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7(7), 1894–1900 (2001).
8. R. A. Sharma, S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, M. Pirmohamed, A. J. Gescher, and W. P. Steward, Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 10(20), 6847–6854 (2004).
9. C. D. Lao, M. T. Ruffin 4th, D. Normolle, D. D. Heath, S. I. Murray, J. M. Bailey, M. E. Boggs, J. Crowell, C. L. Rock, and D. E. Brenner, Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6, 10–13 (2006).
10. G. Garcea, D. J. Jones, R. Singh, A. R. Dennison, P. B. Farmer, R. A. Sharma, W. P. Steward, A. J. Gescher, and D. P. Berry, Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90(5), 1011–1015 (2004).
11. G. Garcea, D. P. Berry, D. J. Jones, R. Singh, A. R. Dennison, P. B. Farmer, R. A. Sharma, W. P. Steward, and A. J. Gescher, Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14(1), 20–125 (2005).
12. S. D. Deodhar, R. Sethi, and R. C. Srimal, Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71, 632–634.
13. B. Lal, A. K. Kapoor, O. P. Asthana, P. K. Agrawal, R. Prasad, P. Kumar, and R. C. Srimal, Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res 13(4), 318–322 (1999).
14. B. Lal, A. K. Kapoor, P. K. Agrawal, O. P. Asthana, and R. C. Srimal, Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res 14(6), 443–447 (2000).
15. P. R. Holt, S. Katz, and R. Kirshoff, Curcumin therapy in inflammatory bowel disease: A pilot study. Dig Dis Sci 50(11), 2191–2193 (2005).
16. S. Durgaprasad, C. G. Pai, Vasanthkumar, J. F. Alvres, and S. Namitha, A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 122(4), 315–318 (2005).
17. M. C. Heng, M. K. Song, J. Harker, and M. K. Heng, Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 143(5), 937–949 (2000).
18. R. Kuttan, P. C. Sudheeran, and C. D. Josph, Turmeric and curcumin as topical agents in cancer therapy. Tumori 73(1), 29–31 (1987).
19. J. S. James, Curcumin: Clinical trial finds no antiviral effect. AIDS Treat News 242, 1–2 (1996).
20. K. B. Soni and R. Kuttan, Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36(4), 273–275 (1992).
21. J. M. Ringman, S. A. Frautschy, G. M. Cole, D. L. Masterman, and J. L. Cummings, A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2(2), 131–136 (2005).
Editors and Affiliations
© 2007 Springer
About this chapter
Cite this chapter
Hsu, CH., Cheng, AL. (2007). CLINICAL STUDIES WITH CURCUMIN. In: Aggarwal, B.B., Surh, YJ., Shishodia, S. (eds) The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol 595. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-46401-5_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-46400-8
Online ISBN: 978-0-387-46401-5